![]() |
市场调查报告书
商品编码
1844373
牛皮癣治疗市场机会、成长动力、产业趋势分析及 2025 - 2034 年预测Psoriasis Treatment Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2025 - 2034 |
2024 年全球牛皮癣治疗市场价值为 281 亿美元,预计到 2034 年将以 9.4% 的复合年增长率增长至 684 亿美元。
这一上升趋势的动力源于全球自体免疫性皮肤病和慢性发炎性疾病发病率的不断上升。医疗保健提供者和患者意识的不断增强,加上新一代生物製剂和标靶小分子药物的不断发展,持续推动市场的发展。个人化治疗方法和先进药物传输技术的新兴创新也在加速市场成长方面发挥重要作用。随着慢性皮肤病负担的加重,对有效、便利且永续治疗方案的需求正在迅速增长。该行业不断发展,拥有多样化的治疗方案,专注于改善患者预后、最大程度地减少疾病发作并提高整体生活品质。个人化医疗解决方案需求的成长以及整个製药业研发活动的加强也促进了该市场的持续扩张。
市场范围 | |
---|---|
起始年份 | 2024 |
预测年份 | 2025-2034 |
起始值 | 281亿美元 |
预测值 | 684亿美元 |
复合年增长率 | 9.4% |
斑块癣和干癣性关节炎是该疾病最常见的表现形式,许多患者会感到关节不适,这增加了对全身性治疗方法的需求。干癣治疗市场属于皮肤病学和免疫学领域,专注于治疗这种以发炎、鳞状病变和全身症状为特征的长期免疫驱动性皮肤病。广泛的治疗选择定义了该领域,从皮质类固醇和维生素D类似物等外用溶液,到IL-17、TNF-α和IL-23抑製剂等口服药物和注射生物製剂,包括旨在实现经济有效的治疗可及性的生物类似药。
2024年,皮质类固醇因其标靶作用机制和成熟的临床疗效,占37.4%的市场。预计到2034年,该细分市场的规模将达到252亿美元,复合年增长率为9.2%。皮质类固醇因其价格实惠、疗效持久和症状缓解迅速等特点而广泛应用。皮质类固醇凭藉其抗发炎和免疫调节的双重特性,仍然是轻度至中度疾病的首选治疗方案,尤其是在门诊治疗中。
2024年,局部治疗领域收入达到156亿美元,这得益于其易用性和较低的全身性副作用风险。局部治疗仍然是症状较轻患者的第一道防线,通常在治疗初期或长期疾病管理中使用。这些剂型包括乳膏、泡沫和凝胶等,经济高效且使用方便,非常适合日常常规使用。
2024年,北美银屑病治疗市场占据41.1%的市场。不断增长的病例数量以及对研发驱动型产品开发的雄厚资金支持推动了该地区的成长。坚实的医疗保健框架支持该地区各国对早期疾病的发现和及时干预。大型製药商的入驻推动了皮肤科药物、生物相似药的上市以及口服治疗方案的创新。同时,优惠的保险政策和公共卫生运动正在改善患者获得先进治疗方案的管道。
影响牛皮癣治疗市场的关键参与者包括强生、辉瑞、默克、Biogen、艾伯维、礼来、Biocon、利奥製药、安进、诺华、UCB Pharma、Arcutis Biotherapeutics、勃林格殷格翰、太阳製药和百时美施贵宝。这些公司继续引领市场创新、临床试验和治疗进步。在牛皮癣治疗市场中运作的公司正在采取多种策略来扩大其影响力和竞争优势。主要工作包括优先研发具有更高疗效和更少副作用的生物製剂和小分子药物。许多公司正在积极扩展其药物管线,开发针对 IL 和 TNF 途径的下一代治疗方法。此外,还在寻求策略合作伙伴关係、收购和授权交易,以加速创新和进入新的区域市场。人们越来越关註生物相似药,以提高可负担性和治疗的可及性。
The Global Psoriasis Treatment Market was valued at USD 28.1 billion in 2024 and is estimated to grow at a CAGR of 9.4% to reach USD 68.4 billion by 2034.
The upward trend is fueled by the growing incidence of autoimmune skin diseases and chronic inflammatory disorders worldwide. Increased awareness among both healthcare providers and patients, coupled with the continuous development of next-generation biologics and targeted small-molecule drugs, continues to push the market forward. Emerging innovations in personalized treatment approaches and advanced drug delivery technologies are also playing a major role in accelerating market growth. As the burden of chronic skin conditions grows, the demand for effective, accessible, and sustainable treatment options is expanding rapidly. The industry continues to evolve with a diverse pipeline of therapies that focus on improving patient outcomes, minimizing flare-ups, and enhancing overall quality of life. The rise in demand for personalized healthcare solutions and greater R&D activity across the pharmaceutical sector are also contributing to the ongoing expansion of this market.
Market Scope | |
---|---|
Start Year | 2024 |
Forecast Year | 2025-2034 |
Start Value | $28.1 Billion |
Forecast Value | $68.4 Billion |
CAGR | 9.4% |
Plaque psoriasis and psoriatic arthritis represent the most prevalent manifestations of the disease, with many patients experiencing joint discomfort that increases the demand for systemic treatment approaches. The psoriasis treatment market falls within the dermatology and immunology sectors, focusing on managing this long-term immune-driven skin disorder marked by inflamed, scaly lesions and systemic symptoms. A broad portfolio of therapeutic choices defines the space, ranging from topical solutions like corticosteroids and vitamin D analogs to oral agents and injectable biologics such as IL-17, TNF-a, and IL-23 inhibitors, including biosimilars designed for cost-effective treatment access.
In 2024, the corticosteroids segment accounted for a 37.4% share due to their targeted mechanism and well-established clinical outcomes. This segment is forecasted to reach USD 25.2 billion by 2034, at a CAGR of 9.2%. Their widespread use stems from affordability, consistent effectiveness, and rapid symptom relief. Corticosteroids remain a go-to solution for mild to moderate disease severity, particularly in outpatient care settings, thanks to their dual anti-inflammatory and immune-modulating properties.
The topical therapies segment generated USD 15.6 billion in 2024, driven by their ease of use and lower risk of systemic side effects. They remain the first line of defense for individuals with milder symptoms, often prescribed at the onset of treatment or for long-term disease management. These formulations, available in forms like creams, foams, and gels, offer cost-effective and user-friendly administration, making them highly favorable for routine application in everyday settings.
North America Psoriasis Treatment Market held 41.1% share in 2024. The regional growth is propelled by increasing case numbers and robust financial backing for research-driven product development. A solid healthcare framework supports early-stage disease detection and timely intervention across countries within the region. The presence of major pharmaceutical manufacturers has spurred innovation in dermatological medications, biosimilar launches, and oral therapeutic options. At the same time, beneficial insurance policies and public health campaigns are improving patient access to advanced treatment solutions.
Key players influencing the Psoriasis Treatment Market include Johnson & Johnson, Pfizer, Merck & Co., Biogen, AbbVie, Eli Lilly, Biocon, LEO Pharma, Amgen, Novartis, UCB Pharma, Arcutis Biotherapeutics, Boehringer Ingelheim, Sun Pharmaceutical, and Bristol-Myers Squibb. These companies continue to lead innovation, clinical trials, and therapeutic advancements within the market. Companies operating in the Psoriasis Treatment Market are adopting multiple strategies to expand their footprint and competitive edge. Key efforts include prioritizing R&D to develop biologics and small-molecule drugs with higher efficacy and reduced side effects. Many firms are actively expanding their drug pipelines with next-gen treatments targeting IL and TNF pathways. Strategic partnerships, acquisitions, and licensing deals are also being pursued to accelerate innovation and enter new regional markets. A growing focus is placed on biosimilars to enhance affordability and treatment accessibility.